Diego S. R.
- Country
- Spain
- Department
- Servicio de Cardiologia
Research Overview
- Evaluation of Finerenone Efficacy and Safety in Heart Failure Patients with Reduced Ejection Fraction Intolerant or Ineligible for Steroidal Mineralocorticoid Receptor Antagonists
- Evaluation of Olpasiran in Reducing First Major Cardiovascular Events in Patients with Elevated Lipoprotein(a) Levels: A Double-Blind, Randomized, Placebo-Controlled Study
- Phase IV, open-label, randomized clinical trial on the effect of intravenous iron on quality of life in elderly patients with Acute Coronary Syndrome.
Data & Insights
Has run more than one trial at 20 of 360 partner sites.
Specializations
Cardiovascular Medicine
Investigator concentrates on acute coronary syndrome, heart failure with preserved ejection fraction, and spontaneous coronary artery dissection.
- Myocardial infarction
- Atherosclerotic cardiovascular disease
- Left ventricular remodeling
Emphasis is placed on secondary prevention and cardiac remodeling pathways.
Breast Cancer Oncology
Research activity includes HER2‑positive breast cancer, triple‑negative breast cancer, and hormone‑receptor‑positive disease.
- Advanced metastatic breast cancer
- Neoadjuvant and adjuvant therapy strategies
- Biomarker‑driven treatment selection
Projects explore targeted agents and resistance mechanisms.
Dermatology and Immune‑Mediated Skin Disorders
Key interests are atopic dermatitis, hidradenitis suppurativa, and bullous pemphigoid.
- Moderate to severe eczema
- Inflammatory skin disease pathways
- Novel biologic therapeutics
Efforts target disease severity reduction and quality‑of‑life improvement.
Lung Cancer and Respiratory Medicine
Investigator engages with non‑small cell lung cancer, EGFR‑mutated disease, and KRAS‑mutated lung carcinoma.
- Targeted therapy resistance
- Advanced stage disease management
- Combination immuno‑oncology approaches
Studies aim to refine molecular classification and therapeutic sequencing.
Metabolic and Endocrine Disorders
Focus areas comprise type 2 diabetes, obesity, and hypertriglyceridemia.
- Cardiometabolic risk reduction
- Impact of novel lipid‑lowering agents
- Integration of endocrine therapy in oncology
Research links metabolic dysregulation to cardiovascular and oncologic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.